Feasibility of adjacent insulin infusion and continuous glucose monitoring via the medtronic combo-set

Journal of Diabetes Science and Technology

Volumn 7, Issue 2, 2013, Pages 381-388

  O'Neal, David N ^a   Adhya, Sumona ^b   Jenkins, Alicia ^a   Ward, Glenn ^a   Welsh, John B ^b   Voskanyan, Gayane ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MEDTRONIC INC   (United States)

Author keywords

Accuracy; Colocalization; Continuous glucose monitoring; Glucose sensing; Insulin delivery

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN LISPRO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ACCURACY; ADULT; ARTICLE; ASPIRATION NEEDLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GLUCOSE SENSOR; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MALE; RECORDER; TEST MEAL; ANALYSIS; BLOOD; CLINICAL TRIAL; DEVICES; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PROCEDURES; EQUIPMENT; METHODOLOGY;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN INFUSION SYSTEMS; INSULIN LISPRO; MALE; MIDDLE AGED;

EID: 84891424866     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700214     Document Type: Article

References (18)

1. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005-12. (Pubitemid 29254858)
2. .Mastrototaro JJ. The MiniMed continuous glucose monitoring system. Diabetes Technol Ther. 2000;2 Suppl 1:S13-8. (Pubitemid 32107467)
3. Mastrototaro JJ, Cooper KW, Soundararajan G, Sanders JB, Shah RV. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study. Adv Ther. 2006;23(5):725-32. (Pubitemid 44955852)
4. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-76.
5. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008;10(5):377-83.
6. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-20.
7. Jenkins AJ, Krishnamurthy B, Best JD, Cameron FJ, Colman PG, Farish S, Hamblin PS, O'Connell MA, Rodda C, Rowley K, Teede H, O'Neal DN. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial. Diabetes Care. 2010;33(6):1242-8.
8. Lindpointner S, Korsatko S, Köhler G, Köhler H, Schaller R, Kaidar R, Yodfat O, Schaupp L, Ellmerer M, Pieber TR, Regittnig W. Use of the site of subcutaneous insulin administration for the measurement of glucose in patients with type 1 diabetes. Diabetes Care. 2010;33(3):595-601.
9. Lindpointner S, Korsatko S, Köhler G, Köhler H, Schaller R, Schaupp L, Ellmerer M, Pieber TR, Regittnig W. Glucose levels at the site of subcutaneous insulin administration and their relationship to plasma levels. Diabetes Care. 2010;33(4):833-8.
10. Moatti-Sirat D, Velho G, Reach G. Evaluating in vitro and in vivo the interference of ascorbate and acetaminophen on glucose detection by a needle-type glucose sensor. Biosens Bioelectron. 1992;7(5):345-52.
11. Linde B, Philip A. Massage-enhanced insulin absorption - increased distribution or dissociation of insulin? Diabetes Res. 1989;11(4):191-4. (Pubitemid 20056225)
12. Hermanides J, Wentholt IM, Hart AA, Hoekstra JB, DeVries JH. No apparent local effect of insulin on microdialysis continuous glucose-monitoring measurements. Diabetes Care. 2008;31(6):1120-2.
13. Peyser T, Zisser H, Khan U, Jovanoviè L, Bevier W, Romey M, Suri J, Strasma P, Tiaden S, Gamsey S. Use of a novel fluorescent glucose sensor in volunteer subjects with type 1 diabetes mellitus. J Diabetes Sci Technol. 2011;5(3):687-93.
14. Diabetes Research in Children Network Study Group, Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes. 2009;10(2):91-6.
15. Rubin RR, Peyrot M. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump. J Diabetes Sci Technol. 2009;3(6):1402-10.
16. Rubin RR, Peyrot M; STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. Diabetes Technol Ther. 2012;14(2):143-51.
17. Jenkins AJ, Krishnamurthy B, Best JD, Cameron FJ, Colman PG, Hamblin PS, O'Connell MA, Rodda C, Teede H, O'Neal DN. An algorithm guiding patient responses to real-time-continuous glucose monitoring improves quality of life. Diabetes Technol Ther. 2011;13(2):105-9.
18. Brauker J. Continuous glucose sensing: future technology developments. Diabetes Technol Ther. 2009;11 Suppl 1:S25-36.